<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Ophthalmology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D92B0BD2-29CE-4C26-82A1-23AEB3502354"><gtr:id>D92B0BD2-29CE-4C26-82A1-23AEB3502354</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>W.B.</gtr:otherNames><gtr:surname>Bainbridge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3674D27C-94ED-40F9-9384-68E8274A926D"><gtr:id>3674D27C-94ED-40F9-9384-68E8274A926D</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Greenwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A32BD451-FBEB-4F05-BEE2-18D6B4FEAB77"><gtr:id>A32BD451-FBEB-4F05-BEE2-18D6B4FEAB77</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902206"><gtr:id>D15C1D6B-7526-46F9-A455-2A8CA7CF4A8C</gtr:id><gtr:title>Development of a therapeutic antibody for a novel angiogenic target</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902206</gtr:grantReference><gtr:abstractText>In several common diseases of the eye, including age-related macular disease and diabetic retinopathy, the network of tiny blood vessels in the light-sensitive part of the eye may undergo major structural changes and grow uncontrollably in a manner severe enough to cause loss of vision. Although some advances have been made in the treatment of these conditions the most effective therapies generally benefit fewer than 50% of patients, and often only delay vision loss. There is therefore an urgent need to develop new therapies, especially of a type that may be useful during the early stages of disease. Our group has discovered a new protein, of previously unknown function, that we have shown to be produced at high levels by abnormal retinal blood vessels and to cause blood vessel cell proliferation. In this project we will generate an antibody that will block the function of this protein, and then create derivatives of the antibody that are safe and effective for use in humans. At the end of the project, if we achieve our objectives, we will be ready to take our new therapy into patients in a Phase I clinical trial.</gtr:abstractText><gtr:technicalSummary>Neovascularisation and vascular remodelling are key clinical features of several pathologies, including wet age-related macular degeneration (AMD), solid tumours and diabetic retinopathy. Regulation or inhibition of vascular changes in these conditions has been shown to slow or arrest disease, but the number of anti-angiogenic therapeutics available is limited, their efficacy is patchy, and the field is constrained by the paucity of useful molecular targets. We have identified a protein of previously unknown function that we have shown to be a potent regulator of angiogenesis. The protein stimulates endothelial cell tube formation in angiogenesis assays, and its activity can be blocked by specific peptides. The aim of this proposal is to i) develop a function-blocking antibody against the protein, ii) demonstrate the efficacy of the antibody in murine models of retinal vascular disease, and iii) develop a humanised version of the antibody for subsequence evaluation in clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2015-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1030770</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention is in the field of molecular physiology and relates to the use of antagonists of Leucine-rich alpha-2-glycoprotein 1 (Lrg1) for use in the treatment or prevention of cancer.</gtr:description><gtr:grantRef>G0902206</gtr:grantRef><gtr:id>A91AF4E2-6F03-4535-81B8-F3E735E19E85</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>gaoY5Me5RSa</gtr:outcomeId><gtr:patentId>WO2013132267</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of Cancer</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The patent covers Magacizumab, a humanised monoclonal antibody against LRG1.</gtr:description><gtr:grantRef>G0902206</gtr:grantRef><gtr:id>422668A9-230B-4057-B5C2-D4831E1A4B23</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56cf11108dee52.59975439</gtr:outcomeId><gtr:patentId>GB1503438.2</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Treatment</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention is in the field of molecular physiology and relates to the use of antagonists of Leucine-rich alpha-2-glycoprotein 1 (Lrg1) for use in the treatment or prevention of vasculoproliferative conditions, particularly in the eye.</gtr:description><gtr:grantRef>G0902206</gtr:grantRef><gtr:id>53C184F6-35F0-43EC-9678-77CCEE2999C9</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>FYMSmrnqU5g</gtr:outcomeId><gtr:patentId>WO2011027129</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of Vasculoproliferative Conditions</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Magacizumab is a humanised monoclonal antibody against LRG1 that is currently being developed with a view to a 'first in man' study in age-related macular degeneration. The antibody inhibits angiogenesis, and as such may also be useful in the treatment of certain cancers. The work to develop the antibody was funded by a DPFS award from the MRC, and a subsequent clinical trials grant from the MRC is now supporting the onward development of the antibody for testing in age-related macular degeneration.</gtr:description><gtr:id>D1644739-2ADC-4F0E-B6FD-FDF33B873A30</gtr:id><gtr:impact>Our antibody has shown impressive efficacy in pre-clinical studies in combination with Eylea, an anti-angiogenic biologic that targets a different angiogenic pathway. This is important because it increases the potential value of our product and supports the design of our proposed first in man study. The antibody is also showing promising efficacy in two mouse tumour models.</gtr:impact><gtr:outcomeId>5458dd52d5b5d9.35904822</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Magacizumab</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We generated 102 monoclonal antibodies against human recombinant leucine-rich alpha-2-glycoprotein 1</gtr:description><gtr:id>A89BA1FA-639B-4654-A0F3-19B7E8BD0CA3</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>SACEZ6fEH3x</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Monoclonal antibodies</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>More than 70 hybridomas that produce antibodies against Lrg1</gtr:description><gtr:id>AD62F513-3251-4033-9DD6-DB270D786170</gtr:id><gtr:impact>These hybridomas were developed in order to identify a function-blocking monoclonal antibody that could be humanised for therapeutic use in human vascular disease.</gtr:impact><gtr:outcomeId>JiPprGLSBPL</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Hybridoma cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AE7F0D17-0800-4522-9899-CDD638FE83AA</gtr:id><gtr:title>LRG1 promotes angiogenesis by modulating endothelial TGF-? signalling.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d33cf2ec743344310cadecc6294d895"><gtr:id>8d33cf2ec743344310cadecc6294d895</gtr:id><gtr:otherNames>Wang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_12406_26_23868260</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902206</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>